May 2003

Childhood Vitiligo and TacrolimusImmunomodulating Treatment for an Autoimmune Disease

Author Affiliations

Not Available


Copyright 2003 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2003

Arch Dermatol. 2003;139(5):651-654. doi:10.1001/archderm.139.5.651

VITILIGO IS an acquired pigmentary disorder, clinically characterized by the development of white macules caused by damage to melanocytes in the affected skin.1 The prevalence of the disease in the United States and Europe has been estimated at around 1%. Half of all patients develop the disease in childhood and adolescence before age 20 years, making vitiligo an important topic of pediatric dermatology.

First Page Preview View Large
First page PDF preview
First page PDF preview